# Ovarian Cancer

- Malignant neoplasm arising from various cell types within the **ovary**, most commonly from **surface epithelial cells**.

## Classifications

### 1. Histological Types

#### A. Epithelial Tumors (90%)

- Serous (high-grade/low-grade)
- Mucinous
- Endometrioid
- Clear cell
- Transitional (Brenner tumor)
- Undifferentiated carcinoma

#### B. Germ Cell Tumors (5–10%)

- Dysgerminoma
- Yolk sac tumor (endodermal sinus tumor)
- Embryonal carcinoma
- Choriocarcinoma
- Teratoma (immature)

#### C. Sex Cord–Stromal Tumors

- Granulosa cell tumor
- Sertoli–Leydig cell tumor
- Thecoma, Fibroma

#### D. Metastatic Tumors

- Krukenberg tumor (usually from gastric carcinoma)

## FIGO Staging

1. `Stage I` – Tumor confined to ovaries/fallopian tubes

   - **IA**: One ovary/tube, capsule intact, no tumor on surface, negative washings
   - **IB**: Both ovaries/tubes, otherwise same as IA
   - **IC**: One/both ovaries/tubes with

     - **IC1**: Surgical spill
     - **IC2**: Capsule rupture before surgery or tumor on surface
     - **IC3**: Malignant cells in ascites/peritoneal washings

1. `Stage II` – Extension to pelvis

   - **IIA**: Extension/implants on uterus or tubes/ovaries
   - **IIB**: Extension to other pelvic tissues

1. `Stage III` – Peritoneal metastasis outside pelvis or retroperitoneal lymph nodes

   - **IIIA1**: Positive retroperitoneal lymph nodes only

     - **IIIA1(i)**: ≤10 mm
     - **IIIA1(ii)**: >10 mm

   - **IIIA2**: Microscopic peritoneal metastasis beyond pelvis
   - **IIIB**: Macroscopic peritoneal metastasis ≤2 cm
   - **IIIC**: Macroscopic peritoneal metastasis >2 cm or involving capsule of liver/spleen (not parenchyma)

1. `Stage IV` – Distant metastasis

   - **IVA**: Malignant pleural effusion (cytologically confirmed)
   - **IVB**: Distant metastasis to parenchymal organs (liver, lung) or inguinal lymph nodes

## Clinical Features

### A. Early Stage (often asymptomatic)

- Vague, non-specific symptoms

### B. Symptoms (late presentation typical)

- **Abdominal distension** / bloating
- **Pelvic/abdominal pain**
- **Early satiety**
- **Urinary urgency/frequency**
- **Change in bowel habits**
- **Weight loss, anorexia**
- **Menstrual irregularities** (esp. in sex-cord tumors)

### C. Signs

- **Pelvic mass** on examination
- **Ascites**
- **Cachexia**
- **Sister Mary Joseph nodule** (umbilical metastasis)
- **Pleural effusion**

## Investigations

### A. For Diagnosis

1. **Pelvic Ultrasound (TVS/TAUS)**

   - Solid-cystic mass
   - Multiloculated with papillary projections
   - Bilaterality
   - Ascites

2. **Serum Tumor Markers** (based on age & type)

   - **CA-125** (epithelial tumors, especially postmenopausal)
   - **AFP, β-hCG, LDH** (germ cell tumors)
   - **Inhibin, estradiol** (sex cord–stromal tumors)

3. **CT/MRI Abdomen & Pelvis**

   - Assess extent, peritoneal involvement

4. **Histopathology**

   - From **laparotomy/biopsy** (definitive diagnosis)

### B. For Causes

- **Genetic testing** (BRCA1/2, Lynch syndrome)
- **Family history** evaluation
- **Risk factors assessment**

  - Nulliparity, infertility, early menarche, late menopause, endometriosis

### C. For Complications

- **CBC** → Anemia
- **LFT/RFT** → Hepatic/renal metastases
- **CXR or CT chest** → Pleural effusion
- **Ascitic fluid cytology**

### D. For Staging & Operability

- **Diagnostic laparoscopy** or **staging laparotomy**
- **Peritoneal washings**
- **Biopsies** (omentum, peritoneum, nodes)

## Management

### Stage I – Disease confined to ovaries/fallopian tubes

#### General Principle

- Goal: Complete surgical staging to determine risk and guide further therapy.

#### Surgical Management

1. **Standard surgery (for women who have completed childbearing)**

   - **TAH + BSO**
   - **Omentectomy** (infracolic)
   - **Peritoneal washings**
   - **Peritoneal biopsies** (pelvic and abdominal peritoneum)
   - **Pelvic and para-aortic lymph node sampling**
   - **Appendectomy** (if mucinous tumor)

2. **Fertility-sparing surgery** (only if all criteria met: young, Stage IA, Grade 1, non-clear cell)

   - **USO** + staging procedure
   - Keep uterus and contralateral ovary

#### Adjuvant Chemotherapy

- **Indications**:

  - Stage IC
  - Grade 3 tumors (any stage)
  - Clear cell histology

- **Regimen**:

  - `Carboplatin` + `Paclitaxel` IV every 3 weeks × 3–6 cycles

- **No chemo** for Stage IA/IB, Grade 1 (low-risk)

---

### Stage II – Disease extends to pelvic organs

#### Surgical Management

- **Cytoreductive surgery**:

  - TAH + BSO
  - Omentectomy
  - Peritoneal staging biopsies
  - Pelvic and para-aortic lymph node dissection
  - Tumor debulking of all visible disease

#### Adjuvant Chemotherapy

- All patients receive:

  - `Carboplatin` + `Paclitaxel` × 6 cycles
  - Optional: `Bevacizumab` in selected high-risk

---

### Stage III – Peritoneal metastasis outside pelvis ± lymph nodes

#### Treatment depends on operability

##### Option 1: Primary Cytoreductive Surgery (CRS)

- Indicated if:

  - Good performance status
  - Resectable disease (no major comorbidities)

###### Surgical Procedure

- TAH + BSO + omentectomy
- Pelvic and para-aortic lymphadenectomy
- Peritonectomy (if needed)
- Debulking liver/spleen capsule, diaphragm, bowel resection if involved
- Goal: **No residual disease (R0)**

##### Option 2: Neoadjuvant Chemotherapy (NACT) + Interval Debulking Surgery (IDS)

- Indicated if:

  - High tumor burden, poor performance status

- **NACT**: `Carboplatin` + `Paclitaxel` × 3 cycles
- **IDS**: Debulking after 3 cycles
- **Adjuvant chemo**: 3 additional cycles

#### Chemotherapy Regimen

- `Carboplatin` (AUC 5–6) + `Paclitaxel` (175 mg/m²) IV every 3 weeks × 6 cycles
- `Bevacizumab` (anti-VEGF):

  - Option in III–IV with high-risk features
  - Given concurrently with chemo, continued as maintenance

#### HIPEC (optional, investigational)

- Hyperthermic intraperitoneal chemotherapy used after CRS in some centers

---

### Stage IV – Distant metastasis (pleural effusion, liver/lung, etc.)

#### If operable and good PS

- **Primary CRS** followed by **6 cycles of chemotherapy**

#### If poor PS or extensive metastasis

- **Neoadjuvant chemotherapy** (`Carboplatin` + `Paclitaxel`) × 3 cycles
- **Interval debulking surgery**
- Continue chemo for total 6 cycles
- Consider `Bevacizumab` + `PARP inhibitors` in BRCA+/HRD+ patients

---

### Maintenance Therapy (for Stage III–IV after chemo response)

#### 1. PARP Inhibitors

- `Olaparib`: BRCA1/2 mutated
- `Niraparib`: All comers (HRD+ or BRCA−)
- Duration: up to 2 years

#### 2. Bevacizumab

- Continued every 3 weeks × 15–18 months in selected high-risk patients (especially III/IV)

---

### Special Considerations

#### Fertility preservation

- Only for Stage IA/Grade 1 (non-clear cell) → USO with staging

#### Pregnancy

- Avoid chemotherapy in 1st trimester
- Surgery can be done in 2nd trimester
- Chemo after 16 weeks if needed (`Carboplatin` preferred)

---

### Palliative Management (advanced/recurrent disease)

- For inoperable patients or recurrence after treatment

  - Re-challenge with platinum-based chemo (if platinum-sensitive >6 months)
  - Non-platinum regimen for platinum-resistant disease
  - PARP inhibitors for BRCA-mutated
  - Palliative surgery/radiation for obstruction, ascites, pain relief
  - Hormonal therapy (e.g., `Letrozole`) in low-grade serous carcinoma
  - Psychosocial support, pain management, hospice if end-stage

---

### Summary Chart: Management by Stage

| Stage     | Primary Treatment                  | Chemo                                        | Maintenance (if advanced)               |
| --------- | ---------------------------------- | -------------------------------------------- | --------------------------------------- |
| **IA–IB** | Surgery ± fertility-sparing        | No chemo (low-risk)                          | No                                      |
| **IC**    | Surgery                            | `Carboplatin` + `Paclitaxel` × 3–6 cycles    | No                                      |
| **II**    | CRS                                | `Carboplatin` + `Paclitaxel` × 6 cycles      | Consider `Bevacizumab`                  |
| **III**   | CRS or NACT + IDS                  | `Carboplatin` + `Paclitaxel` ± `Bevacizumab` | PARP (BRCA+), `Bevacizumab` (high-risk) |
| **IV**    | NACT + IDS (or primary CRS if fit) | Same as Stage III                            | Same                                    |
